Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil
Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil
复制标题
DOI：
10.1093/annonc/mdf035
复制
发表时间：
2002-05-01
影响因子：
50.5
通讯作者：
Sigmund, M
中科院分区：
文献类型：
--
作者：
Frickhofen, N;Beck, FJ;Sigmund, M
卡培他滨是一类新的口服氟嘧啶类药物。它是一种5-氟尿嘧啶（5-FU）前药，由一系列酶激活。已证明激活优先发生在特纳组织中，这可以解释该药物的有效性和毒性的有利平衡。迄今为止，卡培他滨尚未报告过5-FU的一种罕见但可能严重的不良反应--药物毒性。在这里，我们报告一个病人谁经历了严重的和长期的急性冠脉综合征治疗期间卡西他滨。他之前在输注5-FU治疗期间出现过类似症状。因此，卡培他滨应被视为具有心脏毒性潜力的药物。在所有接受卡培他滨治疗的患者中，应特别监测这种不良反应。既往接受氟尿嘧啶治疗期间出现提示心脏毒性症状的患者不应接受卡培他滨治疗。
Capecitabine is a member of a new class of oral fluoropyrimidines. It is a 5-fluorouracil (5-FU) prodrug, activated by a series of enzymes. Activation has been demonstrated to occur preferentially in turner tissue, which may explain the favorable balance of efficacy and toxicity of this drug. Cardiotoxicity, a rare but potentially serious adverse effect of 5-FU, has not been reported for capecitabine to date. Here we report a patient who experienced a severe and prolonged acute coronary syndrome during treatment with capcetabine. He had previously developed similar symptoms during treatment with infusional 5-FU. Capecitabine should thus be considered an agent with cardiotoxic potential. This adverse effect should be specifically monitored in all patients treated with capecitabine. Patients with symptoms suggestive of cardiotoxicity during previous treatment with a fluoropyrimidine should not be treated with capecitabine.